Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Evenity Debut, Copycat Entries Set to Jolt Power Map of Japan Osteoporosis Market
November 21, 2019
- Kyowa Kirin Launches Japan PIII for Acoalan in Preeclampsia
November 21, 2019
- Japan’s 1st HIF-PH Inhibitor Hits Market, Kyorin Pushes Back Lasvic Launch amid Desalex Resupply
November 20, 2019
- 70% of Japanese Still Think HIV Is “Deadly Disease”: Gilead Survey
November 20, 2019
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
- Mitsubishi Chemical to Fully Own Mitsubishi Tanabe to Solidify Healthcare Platform
November 19, 2019
- Fujifilm Kicks Off US PI Study for Topotecan Liposome Drug
November 19, 2019
- Takeda Eyes 12 NME Approvals over Next 5 Years
November 19, 2019
- Shionogi Wins US Approval for Antibiotic Fetroja
November 18, 2019
- Stemirac’s 44 Million Yen Sales Within Expectations, Says Nipro President
November 15, 2019
- Big 3 Generic Firms Enjoy 7.8% Growth, AG Makers Triumph: Jiho Tally
November 15, 2019
- Fujifilm to Make 13 Billion Yen Investment in Gene Therapy Facilities in US
November 15, 2019
- Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally
November 14, 2019
- Kyowa Pharma Set to Accelerate Beyond-the-Pill Growth after Lupin’s Divestment Deal: Chief
November 14, 2019
- Otsuka/Avanir to Carry On Development of Alzheimer’s Agitation Drug
November 14, 2019
- Otsuka’s Pharma Biz Zooms 14.0% in January-September on 4 Global Brands
November 14, 2019
- Ajinomoto, Kanagawa Cancer Center Team Up for Research for Next-Gen Treatment/Diagnosis Technology
November 14, 2019
- Rohto to Snap Up Nitten Pharmaceutical to Tap Into Ethical Eye Drop Arena
November 14, 2019
- Half of R&D Money Going towards Cancer Meds, Exec Says Oncology Will Be GSK’s “Next Respiratory”
November 13, 2019
- AstraZeneca, Omron Healthcare Pair Up to Develop Disease Management Solutions
November 13, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…